NCT06723405Phase 2Completed

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Study sponsor: Evommune, Inc. · EVMN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-11-17Actual
Enrollment · participants71Actual
Source updated2025-12-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 71 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Nov 2025. After: 17 Nov 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview